Log in to save to my catalogue

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_143c8c3d40d4478d8742c856b4915c25

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

About this item

Full title

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer medicine (Malden, MA), 2024-09, Vol.13 (18), p.e70236-n/a

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Background
In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐line platinum‐based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan.
Methods...

Alternative Titles

Full title

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_143c8c3d40d4478d8742c856b4915c25

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_143c8c3d40d4478d8742c856b4915c25

Other Identifiers

ISSN

2045-7634

E-ISSN

2045-7634

DOI

10.1002/cam4.70236

How to access this item